Abstract | BACKGROUND: METHODS: A retrospective cohort study (1 to 15 years) on records of 327 out-patients (217 males, 110 females) without anemia and with chronic renal insufficiency ( creatinine clearance 16 to 75 mL/min) was conducted to estimate the time to development of renal anemia (Hb < 11.5 g/dL in females and Hb < 12.5 g/dL in men), and the time to decrease of Hb by 1 and 2 g/dL or more, irrespective of anemia development. Two treatment groups were analyzed: 142 patients with, and 185 without anti-RAS drugs. RESULTS: Median survival time to development of anemia was 81 months, 59 months to the loss of Hb > 1 g/dL, and 94 months for the loss of Hb > 2 g/dL. Anemia developed significantly earlier in patients with initial Ccr < 40 mL/min and in those with initial Hb < 14 g/dL. In the multivariate analysis (Cox model), male gender, Ccr < 40 mL/min, and Hb < 14 g/dL, in increasing order of relative risk, significantly contributed to prediction of anemia development without any influence of the treatment with anti-RAS drugs. The same results were obtained considering survival to the loss of either Hb > 1 g/dL or Hb > 2 g/dL. CONCLUSIONS:
|
Authors | Antonio Piccoli, Giordano Pastori, Erika Pierobon, Serena Torraca, Michele Andreucci, Massimo Sabbatini, Bruno Cianciaruso |
Journal | Journal of nephrology
(J Nephrol)
2005 Sep-Oct
Vol. 18
Issue 5
Pg. 585-91
ISSN: 1121-8428 [Print] Italy |
PMID | 16299686
(Publication Type: Journal Article)
|
Chemical References |
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
|
Topics |
- Anemia
(chemically induced)
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
(adverse effects)
- Cohort Studies
- Erythropoiesis
(drug effects)
- Female
- Humans
- Kidney Failure, Chronic
(complications)
- Male
- Middle Aged
- Renin-Angiotensin System
(drug effects)
- Retrospective Studies
- Survival Analysis
|